Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MYO-029 · 2 trials · 4 indications
| Name | Type | Description |
|---|---|---|
| MYO-029 | DRUG | - |
Inclusion Criteria: * Written informed consent. * Confirmed clinical and molecular diagnosis of Becker Muscular Dystrophy (BMD), Facioscapulohumeral Muscular Dystrophy (FSHD), or Limb-Girdle Muscular Dystrophy (LGMD) * Independently ambulatory Exclusion Criteria: * Patients with certain clinical ...
MYO-029 is an investigational small molecule being studied for Becker Muscular Dystrophy and other muscular dystrophies, as well as in healthy volunteers. It is being developed by Pfizer, Inc. (NYSE: PFE) for rare disease indications. The drug is currently in Phase 1 clinical development.
MYO-029 is being developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker symbol PFE. The company is studying this investigational small molecule for muscular dystrophy indications, including Becker Muscular Dystrophy.
MYO-029 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Two Phase 1 trials have been completed, one in patients with muscular dystrophy and one in healthy volunteers.
MYO-029 has completed two Phase 1 clinical trials. NCT00104078 studied the drug in adults with Becker Muscular Dystrophy, Facioscapulohumeral Muscular Dystrophy, and Limb-Girdle Muscular Dystrophy, enrolling 108 participants. NCT00563810 evaluated safety, pharmacokinetics, and pharmacodynamics in 72 healthy volunteers.
No alternative names for MYO-029 have been disclosed. The drug is identified by its code name MYO-029 in clinical trial registries and is being developed by Pfizer, Inc. for muscular dystrophy indications.